Results 131 to 140 of about 56,505 (288)
The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity
Abstract Epilepsy comprises a highly heterogeneous group of neurological disorders unified by a persistent predisposition to recurrent seizures, yet driven by remarkably diverse genetic, molecular, and network‐level mechanisms. Advances in genomic technologies have revealed that epilepsy arises from a multilayered genetic architecture encompassing rare
Mohammad Reza Seyedtaghia +4 more
wiley +1 more source
Abstract Objective Variants in the HCN1 gene cause a syndrome of childhood epilepsy and developmental disability with a broad phenotypic range. Many affected children manifest with early infantile epileptic encephalopathy (EIEE) and highly drug‐resistant epilepsy.
Marium N. Khan, Nicholas P. Poolos
wiley +1 more source
Abstract Objective Epilepsy affects approximately 50 million people worldwide and, although primarily attributed to neuronal dysfunction, increasing evidence highlights a critical role of glial cells, particularly astrocytes, in the pathophysiological mechanisms.
Chiara Lötzsch +5 more
wiley +1 more source
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar +4 more
wiley +1 more source
Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist. [PDF]
Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms
Morse BL +7 more
europepmc +2 more sources
Economic burden and cost determinants of epilepsy in Georgia: A longitudinal cost‐of‐illness study
Abstract Objective To assess the economic burden, cost components, and individual‐level determinants of outpatient epilepsy care in adults in Georgia. Methods This longitudinal study of epilepsy‐related costs in adults with active epilepsy attending a tertiary epilepsy centre in Tbilisi collected clinical and sociodemographic data over 6 months. Direct
Sofia Kasradze +5 more
wiley +1 more source
Abstract Objective To evaluate the effectiveness and tolerability of cenobamate in patients with a significant reduction in concomitant antiseizure medication (ASM) in European cenobamate Early Access Programs (EAPs). Method Anonymized patient data from real‐world studies/registries associated with European cenobamate EAPs were pooled.
Vicente Villanueva +25 more
wiley +1 more source
Abstract Objectives The aim of the present study was to investigate the analgesic effects of repetitive transcranial magnetic stimulation over the primary motor cortex (M1‐rTMS) using different stimulation parameters to explore the optimal stimulus condition for treating neuropathic pain.
Nobuhiko Mori +5 more
wiley +1 more source
Data on carbamazepine prolonged dosage forms use for treatment of epilepsy are presented in current review. Expediency of carbamazepine prolonged forms use in patients with different epilepsy forms and types of seizures is demonstrated.
G. N. Avakyan, S. G. Burd
doaj
Abstract Objective Stiripentol and fenfluramine are approved treatments for Dravet syndrome (DS), but real‐world data comparing their effectiveness and combined use remain limited. Our study aims to explore associations between treatment with stiripentol, fenfluramine, and their combination and clinical outcomes in patients with DS.
Paolo Surdi +7 more
wiley +1 more source

